Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects

European Journal of Clinical Pharmacology

Volumn 56, Issue 4, 2000, Pages 299-304

  Ebert, U ^a   Thong, N Q ^a   Oertel, R ^a   Kirch, W ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Electroencephalogram; Lamotrigine; Pharmacokinetics

Indexed keywords

CIMETIDINE; LAMOTRIGINE; PLACEBO; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; ELECTROENCEPHALOGRAM; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033926065     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000146     Document Type: Article

References (33)

1. 1. Miller AA, Wheatley P, Sawyer DA, Baxter MG, Roth B (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. anticonvulsant profile in mice and rats. Epilepsia 27: 483-489
2. 2. Leach MJ, Marden CM, Miller AA (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. neurochemical studies on the mechanism of action. Epilepsia 27: 490-497
3. 3. Binnie CD, Debets RMC, Engelsman M, Meijer JW, Meinardi H, Overweg J, Peck AW, van Wieringen A, Yuen WC (1989) Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 4: 222-229
4. 4. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW (1987) Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 42: 535-541
5. 5. Depot M, Powell JR, Messenheimer JA, Cloutier G, Dalton MJ (1990) Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 48: 346-355
6. 6. Garnett WR (1997) Lamotrigine: pharmacokinetics. J Child Neurol 12: S10-S15
7. 7. Dickins M, Sawyer DA, Morley TJ, Parsons DN (1995) Lamotrigine: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs. Raven Press, New York, pp 871-875
8. 8. Rambeck B, Wolf P (1993) Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 25: 433-443
9. 9. May TW, Rambeck B, Jürgens U (1996) Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 18: 523-531
10. 10. Battino D, Croci D, Estienne M, Pisani F, Avanzini G (1997) Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy. Ther Drug Monit 19: 252-260
11. 11. Ogiso T, Ito Y, Iwaki M, Yoneda I, Horibe Y (1989) Effects of anticonvulsants on plasma levels and enterohepatic circulation of valproic acid and on hepatic drug metabolizing activities in rats. J Pharmacobiodyn 12: 255-263
12. 12. May TW, Rambeck B, Jürgens U (1999) Influence of oxcarbazepine and methsuximide on lamotrgine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 21: 175-181
13. 13. Anderson GD, Yau MK, Gidal BE, Harris SJ, Levy RH, Lai AA, et al (1996) Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 60: 145-156
14. 14. Yuen AWC, Land G, Weatherley C, Peck AW (1992) Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 33: 511-513
15. 15. Bourgeois BDF (1988) Pharmacologic interactions between valproate and other drugs. Am J Med 84[suppl 1]: 29-33
16. 16. Doostar H, Grant MH, Melvin WT, Wolf CR, Burke MD (1993) The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human hepG2 hepatoma cells. Biochem Pharmacol 46: 629-635
17. 17. Gallicano KD, Sahai J, Shukla VK, Seguin I, Pakuts A, Kwok D, et al (1999) Induction of zidovudine glucuronidation and animation pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol 48: 168-179
18. 18. Somogyi A, Muirhead M (1987) Pharmacokinetic interactions of cimetidine 1987. Clin Pharmacokinet 12: 321-366
19. 19. Miners JO, Attwood J, Birkett DJ (1984) Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. Clin Pharmacol Ther 35: 480-486
20. 20. Patwardhan RV, Yarborough GW, Desmond PV, Johnson RF, Schenker S, Speeg KV (1980) Cimetidine spares the glucuronidation of lorazepam and oxazepam. Gastroenterol 79: 912-916
21. 21. Wright JT, Goodman RP, Bethel AMM, Lambert CM (1984) Cimetidine and dapsone acetylation. Drug Metab Dispos 12: 782-783
22. 22. Emery S, Oldham HG, Norman SJ, Chenery RJ (1985) The effects of cimetidine and ranitidine on paracetamol glucuronidation and sulphation in cultured rat hepatocytes. Biochem Pharmacol 34: 1415-1421
23. 2-receptor antagonists in vivo and in vitro in the rat and in man. J Clin Invest 73: 383-391
24. 24. Oertel R, Richter K, Gramatté T, Kirch W (1998) Determination of drugs in biological fluids by high-performance liquid chromatography with on-line sample processing. J Chromatogr A 797: 203-209
25. 25. Jasper HH (1958) The ten-twenty electrode system of the International Federation. Electroencephalogr Clin Neurophysiol 10: 371-375
26. 26. Ebert U, Siepmann M, Oertel R, Wesnes KA, Kirch W (1998) Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol 38: 720-726
27. 27. Schober F, Dimpfel W (1992) Relation between psychometric tests and quantitative topographic EEG in pharmacology. Int J Clin Pharmacol Ther Toxicol 30: 428-430
28. 28. Herrmann WM, Kubicki St, Künkel H, Kugler J, Lehmann D, Maurer K, et al (1989) Empfehlungen der Deutschen EEG-Gesellschaft für das Mapping von EEG-Parametern (EEG-und EP-Mapping). Z Elektroenzephalographie Elektromyographie 20: 125-132
29. 29. Pfeifer S, Pflegel P, Borchert HH (1995) Pharmakokinetische Analyse. In: Pfeifer S, Pflegel P, Borchert HH (eds) Biopharmazie. Mosby, Ullstein, pp 87-137
30. 30. Wootton R, Soul-Lawton J, Rolan PE, Fook Sheung CTC, Cooper JDH, Posner J (1997) Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol 43: 23-27
31. 31. Yuen WC, Peck AW (1988) Lamotrigine pharmacokinetics: oral and i.v. infusion in man. Epilepsia 28: 582-586
32. 32. Greenblatt DJ, Allen MD, Locniskar A, Harmatz JS, Shader RI (1979) Lorazepam kinetics in the elderly. Clin Pharmacol Ther 26: 103-113
33. 33. van Wieringen A, Binnie CD, Meijer JWA, Peck AW, de Vries J (1989) Comparison of the effects of lamotrigine and phenytoin on the EEG power spectrum and cortical and brainstem-evoked responses of normal human volunteers. Neuropsychobiology 21: 157-169